• Alnylam Pharmaceuticals announced first-in-human results showing its Regeneron-partnered CIDEBsiRNA rapidly normalized liver fat in patients with metabolic dysfunction-associated steatotic liver disease.
• A single injection also improved liver injury markers, with effects sustained through 36 weeks in the ongoing Phase 1/2 trial.
• Results were presented at AASLD's The Liver Meeting 2026 and published simultaneously in The New England Journal of Medicine.
• Regeneron leads development and holds exclusive commercialization rights for the investigational treatment.
• The partnership entitles Alnylam to development milestones and tiered, double-digit royalties up to 20%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101000BIZWIRE_USPR_____20261110_BW694883) on November 10, 2026, and is solely responsible for the information contained therein.